DiviTum - TK Activity Assay

About

DiviTum measures thymidine kinase (TK) activity in a serum sample. The activity is proportional to the amount of dividing cells in contact with the blood stream in the whole body. Since the most prominent feature of cancer is uncontrolled cell division, this allows for determination of tumour aggressiveness.

General information

Measurement of cell division can help detect cancer earlier and increase the chance of a better prognosis. See more on http://biovica.com/?page_id=355

Clinical application

DiviTum, measuring cell division, a novel tool in clinical chemistry, for use in preventive medicine, primary care and oncology. See more on http://biovica.com/?page_id=101

Research application

Quantitating whole body cell proliferation activity

Summary

TK is an enzyme expressed in the G1-S cell division stage to supply the thymidine triphosphate necessary for cell division. Thus TK has indirectly been used for measuring cell division in cell culture by addition of radioactive thymidine followed by measurement of radioaktivity incorporated in the DNA (so called thymidine incorporation analysis). Presence of active TK in serum and its correlation to tumour disease was shown 1982. Results since then, obtained with radioactive assays, e.g. Prolifigen® TK-REA (DiaSorin S.r.L), have demonstrated that levels of serum TK in tumour patients correspond to the amount of dividing tumour cells. Serum TK activity assays have found their major clinical application for the prognosis and the monitoring of therapy in blood malignancies. Elevated levels of TK activity have also been linked to solid tumours20: prostatic carcinoma and lung cancer. Another reason for increased serum TK activity is vitamin B12 deficiency, when causing megaloblastic anemia, because of the interference with thymidine monophosphate supply. Further, certain virus infections triggering the cells into G1-S stage give transient elevated serum TK activity in acute stage of infection. These viruses belong mainly to the Herpes virus group. Particularly generalized zoster and cytomegalovirus infection in immunosuppressed patients must be verified and further investigated. With the high sensitivity obtained by DiviTum® it has also been noted that transient increase in S-TK occurs during wound healing after e.g. surgery. These increases i.e. after acute viremia and trauma normalize within 5 – 8 weeks depending of severity of damage33. TK activity has also been found in body fluids other than serum, such as cerebrospinal fluid (CSF), pleural fluid and ascitic fluid in connection with tumour disease.

Research topic

Oncology

Applications

Serum

Calibration curve

Limit of detection

5 Du/l

References to summary

• Aul C, Germing U, Gattermann N, Sohngen D, Heyll A. [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome]. Dtsch Med Wochenschr. 1996 Sep 13;121 (37):1113-8
• Bergstrom R, Gronowitz JS, Killander A, Brenning G, Kallander CF, Simonsson B. Biochemical markers in multiple myeloma: a multivariate analysis. Br J Haematol. 1988 May;69 (1):47-53
• Bombardieri E, Bogni A, Cortinois A, Grasselli G, Seregni E, Crippa F, Castellani MR. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients. J Biol Regul Homeost Agents. 1994 Oct-Dec;8 (4):121-5
• Ellims PH, Van der Weyden MB, Medley G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Res. 1981 Feb;41 (2):691-5
• Emmerich B, Hallek M, Kuhn-Hallek I, Stern S, Schick HD, Busch R, Senekowitsch R, Ostwald M, Wanders L. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996 Aug;22 (5-6):439-47
• Emmerich B, Wanders L, Strohmeyer S, Hallek M. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol. 1992 Jul;65 (1):1-5
• Eneroth P, Lewenhaupt A, Ekman P, Nilsson B. Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol. 1990 Aug;66 (2):182-7
• ESTBORN B, REICHARD P. Utilization of desoxyribosides in the synthesis of polynucleotides. J Biol Chem. 1951 Feb;188 (2):839-46
• Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S, Kallander CF. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer. 1990 Aug 15;66 (4):722-32
• Gronowitz JS, Simonsson B, Hagberg H, Kallander CF. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer. 1983 Apr;47 (4):487-95
• Hagberg H, Kallander CF, Steinholtz L, Gronowitz JS, Bergh J. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers. Cancer. 1986 Jul 1;58 (1):111-8
• Hagberg H, Pettersson U, Diderholm H, Kallander FR, Gronowitz JS. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer. 1984 Jan 15;33 (1):5-12
• Kallander CF, Karlstrom AR, Neumuller M, Gronowitz JS. Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA. Mol Cell Biochem. 1990 Jan 18;92 (1):23-35
• Kallander CF, Simonsson B, Brenning G, Killander A, Ahre A, Gronowitz JS. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br J Haematol. 1985 Oct;61 (2):215-24
• Kallander CF, Simonsson B, Hagberg H, Gronowitz JS. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer. 1984 Dec 1;54 (11):2450-5
• Larson A, Fritjofsson A, Norlen BJ, Gronowitz JS, Ronquist G. Prostate specific acid phosphatase versus five other possible tumour markers: a comparative study in men with prostatic carcinoma. Scand J Clin Lab Invest Suppl. 1985;179:81-8
• Lewenhaupt A, Ekman P. Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information. Acta Oncol. 1991;30 (2):173-5
• Munch-Petersen B, Zhu C, Harlow LS, Berenstein D, Munch-Petersen S. Effect of C-terminal of human cytosolic thymidine kinase (TK1) on in vitro stability and enzymatic properties. Nucleosides Nucleotides Nuclei. 2006;25 (9-11):1185-8
• Musto P, Carotenuto M, Valvano MR, Parlatore L, Modoni S, Perla G, Scalzulli P, D'Arena G, Falcone A, Bodenizza C. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia. Br J Haematol. 1995 May;90 (1):125-30
• Nakao K, Fujioka S. Thymidine kinase activity in the human bone marrow from various blood diseases. Life Sci. 1968 Apr 15;7 (8):395-9
• Neumuller M, Kallander CF, Gronowitz JS. Detection and characteristics of DNA polymerase activity in serum from patients with malignant, viral, or B12-deficiency disease. Enzyme. 1989;41 (1):6-16
• Nilsson S, Norlen BJ, Gronowitz S, Eklov S, Letocha H. Deoxythymidine kinase in the staging of prostatic adenocarcinoma. Prostate. 1996 Jul;29 (1):15-9
• Olding-Stenkvist E, Gronowitz JS, Kallander CF. Varicella zoster virus deoxythymidine kinase is present in serum before the onset of varicella. Scand J Infect Dis. 1989;21 (3):255-7
• Olsson U, Einarsson R, Lagerstedt AS, Eriksson S, von Euler H. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med. 2004 Sep-Oct;18 (5):696-702
• Persson L, Hagberg H, Kallander CF, Gronowitz JS. Deoxythymidine-kinase in cerebrospinal fluid: a new potential "marker" for brain tumours. Acta Neurochir (Wien). 1984;73 (1-2):1-12
• Rose IS, Brumley J, Hayman RJ, van der Weyden MB. Folate-deficient human lymphoblasts: changes in deoxynucleotide metabolism and thymidylate cycle activities. Eur J Haematol. 1991 Aug;47 (2):109-14
• Sandstrom H, Wahlin A, Eriksson M, Bergstrom I. Serum thymidine kinase in congenital dyserythropoietic anaemia type III. Br J Haematol. 1994 Jul;87 (3):653-4
• Schroder T, Kallander C, Killander A, Gronowitz S, Glimelius B, Hagberg H. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis. Scand J Haematol. 1984 Jul;33 (1):59-67
• Simonsson B, Kallander CF, Gronowitz JS, Nilsson K. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur J Haematol. 1987 Apr;38 (4):331-7
• Suki S, Swan F Jr, Fritsche HA, Tucker S, Rodriguez MA, McLaughlin P, Redman JR, et al., Romaguera J, Hagemeister FB, Velasquez WS. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma. 1995 Jun;18 (1-2):87-92
• Sundstrom C, Kallander C, Gronowitz JS, Rehn S, Glimelius B. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas. Br J Cancer. 1995 May;71 (5):1099-105
• Tufveson G, Totterman TH, Kallander CF, Hagstrom A, Gronowitz JS. Serum thymidine-kinase and cytomegalovirus-specific antibodies after renal transplantation. Transplant Proc. 1988 Jun;20 (3):405-7
• Wilmanns W, Muller D, Hartje J, Bock HE. [Thymine nucleotide synthesis and proliferation of bone marrow cells in megaloblastic anemias under the effect of vitamin B 12]. Klin Wochenschr. 1967 Feb 15;45 (4):176-88
• Yamada K, Naito K, Doi S. Serum deoxythymidine kinase as a progressive marker of hematological malignancy. Nagoya J Med Sci. 1990 Mar;52 (1-4):19-26

Contact

BioVendor – Laboratorni medicína a.s. is the exclusive Biovica distributor for the Czech Republic, Germany and the USA.

If you are interested in this product, please contact:

frybortova@biovendor.com (Czech Republic)

infoEU@biovendor.com (Germany)

infoUSA@biovendor.com (USA)

By research topic:

• Oncology

By molecule:

• Thymidine kinase